Pal Shreyashi, Arisha Ruhi, Mazumder Papiya Mitra
Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, 835215, India.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):25-46. doi: 10.1007/s00210-024-03332-z. Epub 2024 Aug 3.
Modern dietary habits and stressed lifestyle have escalated the tendency to develop functional gastrointestinal disorders (FGIDs) through alteration in the gut-brain-microbiome axis. Clinical practices use symptomatic treatments, neglect root causes, and prolong distress in patients. The past decade has seen the evolution of various interventions to attenuate FGIDs. But clinical translation of such studies is very rare mostly due to lack of awareness. The aim of this review is to meticulously integrate different studies and bridge this knowledge gap. Literature between 2013 and 2023 was retrieved from PubMed, ProQuest, and Web of Science. The data was extracted based on the PRISMA guidelines and using the SYRCLE's risk of bias and the Cochrane Risk of Bias tools, quality assessment was performed. The review has highlighted molecular insights into the coexistence of FGIDs, stress, and gut dysbiosis. Furthermore, novel interventions focusing on diet, probiotics, herbal formulations, and phytoconstituents were explored which mostly had a multitargeted approach for the management of the diseases. Scientific literature implied positive interactions between the interventions and the gut microbiome by increasing the relative abundance of beneficial bacteria and reducing stress-related hormones. Moreover, the interventions reduced intestinal inflammation and regulated the expression of epithelial tight junction proteins in different in vivo models. This systematic review delves deep into the preclinical interventions to manage coexisting FGIDs, stress, and gut dysbiosis. However, in most of the discussed studies, long-term risks and toxicity profile of the interventions are lacking. So, it is necessary to highlight them for improved clinical outcomes.
现代饮食习惯和紧张的生活方式通过改变肠-脑-微生物群轴,增加了患功能性胃肠疾病(FGIDs)的倾向。临床实践采用对症治疗,忽视根本原因,延长了患者的痛苦。在过去十年中,出现了各种减轻FGIDs的干预措施。但由于缺乏认识,这类研究的临床转化非常罕见。本综述的目的是精心整合不同的研究,填补这一知识空白。从PubMed、ProQuest和Web of Science检索了2013年至2023年的文献。根据PRISMA指南提取数据,并使用SYRCLE偏倚风险工具和Cochrane偏倚风险工具进行质量评估。该综述强调了对FGIDs、压力和肠道菌群失调共存的分子见解。此外,还探索了以饮食、益生菌、草药配方和植物成分为主的新型干预措施,这些措施大多采用多靶点方法来管理疾病。科学文献表明,这些干预措施通过增加有益细菌的相对丰度和减少与压力相关的激素,与肠道微生物群之间存在积极的相互作用。此外,在不同的体内模型中,这些干预措施减少了肠道炎症,并调节了上皮紧密连接蛋白的表达。本系统综述深入探讨了管理FGIDs、压力和肠道菌群失调共存的临床前干预措施。然而,在大多数讨论的研究中,缺乏干预措施的长期风险和毒性概况。因此,有必要强调这些问题以改善临床结果。